tbuckley/cabot-search huggingface dataset:
Errors in Table
Authors: Gary B. Deutsch
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
Authors: Natasha Szuber, Rangit R. Vallapureddy, Domenico Penna, Terra L. Lasho, Christy Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: American Journal of Hematology (2018)

Abstract Between 1967 and 2017, 361 patients with myeloproliferative neoplasms (MPN), age ≤ 40 years, were seen at our institution, constituting 12% of all MPN patients ( n = 3023) seen during the same time period; disease‐specific incidences were 12% in polycythemia vera (PV; n = 79), 20% in essential thrombocythemia (ET; n = 219) and 5% in primary myelofibrosis (PMF; n = 63). Compared to their older counterparts, younger patients were more likely to present with low risk disease ( P &lt; .001) and display female preponderance in ET ( P = .04), lower incidence of arterial events overall ( P &lt; .001), and higher incidence of venous thrombosis in PV ( P = .01). Younger patients were also more likely to express CALR mutations, in ET and PMF, normal karyotype, in PV and PMF, and lower incidence of high molecular risk mutations in PMF ( P significant in all instances ). Over median follow‐up of 11.3, 13, and 7.1 years for PV, ET, and PMF, leukemic transformations were respectively documented in 4%, 2%, and 10% ( P values 0.1‐0.9) while incidences of fibrotic progression in PV (22%) and ET (16%) were expectedly higher in young patients, because of their longer survival ( P &lt; .001). Median survival in young patients was 37 years for PV, 35 for ET and 20 for PMF; the corresponding values were 22, 22, and 8 years for ages 41‐60 years and 10, 11, and 3 years for ages &gt;60 years ( P &lt; .001). Young MPN patients comprise a unique disease subset defined by an attenuated‐risk cytogenetic and mutational backdrop and conspicuously longer survival compared to their older counterparts, which requires assertion during patient counseling.
Abstract 16858: Computer Assisted Ventricular Surgery: a Novel Tool to Improve Outcome of Ventricular Restoration Surgery
Authors: Gábor Szabó, Christopher Gose, Fabian Rengier, Thomas Hilbel, Ulrich Kauczor, Matthias Karck
Journal: Circulation (2016)

Introduction: The clinical data of surgical ventricular restoration are controversial (Stich trial vs. Registry Data). Accurate assessment of left ventricular morphology and function as well as car...
<i>Notes from the Field:</i> Inspection of 59 “Vape Shops” — United States, October–November, 2016
Authors: David Keith, Kristina Peters, Corinne G. Husten
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

In 2009, the Food and Drug Administration (FDA) was given the authority to regulate the manufacture, marketing, and distribution of tobacco products (1).Effective August 2016, this authority was extended to all tobacco products, including electronic cigarettes (e-cigarettes) (2).Section 704(a)(1) of the Food, Drug, and Cosmetic Act gives FDA authority to conduct investigations and inspections of manufacturers (i.e., any person who manufactures, fabricates, assembles, processes, or labels a tobacco product or imports a finished tobacco product for sale or distribution in the United States) to ensure compliance with applicable federal requirements (1,2).*In October and November 2016, unannounced inspections were conducted in 59 "vape shops" to learn about business and manufacturing practices, including whether establishments were retailers or manufacturers, and, among manufacturers, how the products sold were manufactured and whether the manufacturers were aware of FDA regulations regarding tobacco products.This report summarizes these first 59 inspections, which showed a lack of quality assurance programs, standard operating procedures, and full labeling of ingredients by the inspected manufacturers.Vape shops engage in activities that include selling electronic nicotine delivery systems (ENDS), ENDS replacement pieces, and ENDS premixed flavored "e-liquids" and mixing or preparing combinations of liquid nicotine, flavors, and other liquids for sale to consumers.Before an inspection was initiated, a notice of inspection was issued to the most senior staff member at the shop, who also received a summary of the findings once the inspection was closed.Sixty establishments in four states were selected; one smoking lounge that did not sell or manufacture products was excluded from subsequent analysis.The 59 inspected shops included 31 retailers that only sold finished products, 27 that were both manufacturers and retailers, and one manufacturer that did not sell to consumers.Personnel at all shops reported being aware of FDA tobacco product regulation.The remainder of this report focuses on the 28 manufacturers.Among the 28 manufacturers, 14 were small businesses employing approximately three persons each; the remaining 14 reported having a parent corporation, a subsidiary, or an * https://www.fda.gov/TobaccoProducts/Labeling/default.htm.
Outbreak of Adenovirus in a Neonatal Intensive Care Unit
Authors: Julia S. Sammons, Erin H. Graf, Sara Townsend, Cindy L. Hoegg, Sarah A. Smathers, Susan E. Coffin, Katie Williams, Stephanie L. Mitchell, Ursula Nawab, David Munson, Graham Quinn, Gil Binenbaum
Journal: Ophthalmology (2018)
Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin
Authors: Björn Hiller, Anja Hoppe, Christa Haase, Christina Hiller, Nadja Schubert, Werner Müller, Martin A.M. Reijns, Andrew P. Jackson, Thomas A. Kunkel, Jörg Wenzel, Rayk Behrendt, Axel Roers
Journal: Cancer Research (2018)

Because of imperfect discrimination against ribonucleoside triphosphates by the replicative DNA polymerases, large numbers of ribonucleotides are incorporated into the eukaryotic nuclear genome during S-phase. Ribonucleotides, by far the most common DNA lesion in replicating cells, destabilize the DNA, and an evolutionarily conserved DNA repair machinery, ribonucleotide excision repair (RER), ensures ribonucleotide removal. Whereas complete lack of RER is embryonically lethal, partial loss-of-function mutations in the genes encoding subunits of RNase H2, the enzyme essential for initiation of RER, cause the SLE-related type I interferonopathy Aicardi-Goutières syndrome. Here, we demonstrate that selective inactivation of RER in mouse epidermis results in spontaneous DNA damage and epidermal hyperproliferation associated with loss of hair follicle stem cells and hair follicle function. The animals developed keratinocyte intraepithelial neoplasia and invasive squamous cell carcinoma with complete penetrance, despite potent type I interferon production and skin inflammation. These results suggest that compromises to RER-mediated genome maintenance might represent an important tumor-promoting principle in human cancer.Significance: Selective inactivation of ribonucleotide excision repair by loss of RNase H2 in the murine epidermis results in spontaneous DNA damage, type I interferon response, skin inflammation, and development of squamous cell carcinoma. Cancer Res; 78(20); 5917-26. ©2018 AACR.
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Authors: Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Arata Azuma, Thomas J. Bice, Demosthenes Bouros, Kevin K. Brown, Harold R. Collard, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, R. Gisli Jenkins, Takeshi Johkoh, Ella A. Kazerooni, Masanori Kitaichi, Shandra L. Knight, George Mansour, Andrew G. Nicholson, Sudhakar N. J. Pipavath, Ivette Buendía-Roldán, Moisés Selman, William D. Travis, Simon L. F. Walsh, Kevin C. Wilson
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.The evidence syntheses were discussed and recommendations formulated by a multidisciplinary committee of IPF experts. The evidence was appraised and recommendations were formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach.The guideline panel updated the diagnostic criteria for IPF. Previously defined patterns of usual interstitial pneumonia (UIP) were refined to patterns of UIP, probable UIP, indeterminate, and alternate diagnosis. For patients with newly detected interstitial lung disease (ILD) who have a high-resolution computed tomography scan pattern of probable UIP, indeterminate, or an alternative diagnosis, conditional recommendations were made for performing BAL and surgical lung biopsy; because of lack of evidence, no recommendation was made for or against performing transbronchial lung biopsy or lung cryobiopsy. In contrast, for patients with newly detected ILD who have a high-resolution computed tomography scan pattern of UIP, strong recommendations were made against performing surgical lung biopsy, transbronchial lung biopsy, and lung cryobiopsy, and a conditional recommendation was made against performing BAL. Additional recommendations included a conditional recommendation for multidisciplinary discussion and a strong recommendation against measurement of serum biomarkers for the sole purpose of distinguishing IPF from other ILDs.The guideline panel provided recommendations related to the diagnosis of IPF.
Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma
Authors: Sachiko Konosu-Fukaya, Kei Omata, Yuta Tezuka, Yoshikiyo Ono, Yayoi Aoyama, Fumitoshi Satoh, Fumiyoshi Fujishima, Hironobu Sasano, Yasuhiro Nakamura
Journal: Endocrine Pathology (2018)
Annals Graphic Medicine - One Artist's Look at Anxiety and Depression
Authors: William J. Doan
Journal: Annals of Internal Medicine (2018)

Web Exclusives4 September 2018Annals Graphic Medicine - One Artist's Look at Anxiety and DepressionFREEWilliam J. Doan, BA, MFA, PhDWilliam J. Doan, BA, MFA, PhDPennsylvania State University, University Park, Pennsylvania (W.J.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G17-0020 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Pennsylvania State University, University Park, Pennsylvania (W.J.D.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G17-0020.Author/Illustrator Information: William J. Doan, BA, MFA, PhD, is an artist and scholar whose work includes visual art, solo performance, historiography, and playwriting. He is currently Director of the School of Theatre at the Pennsylvania State University.Author Contributions: Conception and design: W.J. Doan.Drafting of the article: W.J. Doan.Final approval of the article: W.J. Doan.Administrative, technical, or logistic support: W.J. Doan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Art and Science of Nursing 4 September 2018Volume 169, Issue 5Page: W13-W29KeywordsAnxietyConflicts of interestDisclosureHealth care ePublished: 4 September 2018 Issue Published: 4 September 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Fairness, more than any other cognitive mechanism, is what explains the content of folk-economic beliefs
Authors: Nicolas Baumard, Coralie Chevallier, Jean-Baptiste André
Journal: Behavioral and Brain Sciences (2018)

Abstract We applaud Boyer &amp; Petersen's (B&amp;P's) article on economic folk beliefs. We believe that it is crucial for the future of democracy to identify the cognitive systems through which people form their beliefs about the working of the economy. In this commentary, we put forward the idea that, although many systems are involved, fairness is probably the main driver of folk-economic beliefs.
Understanding the Risk of Treatment Failure After Discontinuation of Long-Term Antipsychotic Treatment
Authors: Pál Czobor, Jan Volavka
Journal: American Journal of Psychiatry (2018)

NAPLS-2 risk calculator using a comparable data set from an Asian sample and only the second to do so with a non-NAPLS sample, although the NAPLS-2 risk calculator did not fit our SHARP data as well as it fit the original sample.We believe that our slightly lower AUC is to be expected given a completely independent sample, which may be subject to the issue of statistical "shrinkage" (i.e., less good fit when applying regression models to new samples).This result suggests that the NAPLS-2 risk calculator has some generalizability to an Asian country and may have usefulness in clinical applications in China.This information provides a critical first step in the implementation of the NAPLS-2 risk calculator for the clinical high-risk population in China and supports the validity of the risk calculator in novel samples.However, as emphasized by Cannon et al. (1) and Carrión et al. (2) in the October 2016 issue of the Journal, the risk calculator remains experimental.At this point, it should be used only in research settings and with clinicians who have had rigorous SIPS training (SIPS scores being at the core of the model) and not yet used in general clinical settings with individuals until its clinical utility and properties are validated more firmly.
Abstract 13362: STIM1 and STIM2 are Required in Smooth Muscle Development and Function
Authors: Salvatore Mancarella, Hui Gao, Rosario Scalia, Steven Houser, Donald Gill
Journal: Circulation (2011)

STIM1 and STIM2 control Ca2+ signaling in several cell types by activating the store operated Ca2+ entry (SOCE). Whereas their role and functions are well studied in immune cells, their role in vas...
Advances in Transcriptomics
Authors: Robert C. Wirka, Milos Pjanic, Thomas Quertermous
Journal: Circulation Research (2018)

Whole-genome transcriptional profiling has become a standard genomic approach to investigate biological processes. RNA sequencing (RNAseq) in particular has witnessed myriad applications in genetics and various biomedical fields. RNAseq involves a relatively simple experimental protocol of RNA extraction and cDNA library preparation and, because of decreasing next-generation sequencing cost and lower computational burden for data processing, has obtained a central role in the modern biology. The recent application of RNAseq methodology to single-cell transcriptional profiling has enabled the more precise characterization of cell lineage and cell state genetic profiles. The development of bioinformatic and statistical tools has provided for differential gene expression analysis, RNA isoform analysis, haplotype-specific analysis of gene expression (allele-specific expression), and analysis of expression quantitative trait loci. We give an overview of these and recent developments in RNAseq methodology with emphasis on quality control, read mapping, feature counting, differential gene expression, allele-specific expression and expression quantitative trait loci analysis, and fusion transcript detection. We describe utilization of RNAseq as a diagnostic tool in Mendelian diseases, complex phenotypes, and cancer and give an overview of long read RNAseq technology. Furthermore, we discuss in detail the recent revolution in single-cell transcriptomics that is reshaping modern biology.
Are Bacteria Transplants the Future of Eczema Therapy?
Authors: Jennifer Abbasi
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report
Authors: Jacob Appelbaum, David Wells, Joseph B. Hiatt, Gideon Steinbach, F. Marc Stewart, Hannah Thomas, Paul Nghiem, Raj P. Kapur, John A. Thompson, Shailender Bhatia
Journal: Journal for ImmunoTherapy of Cancer (2018)

<h3>Background</h3> Immune checkpoint inhibitors (ICIs) are the treatment of choice for several cancers and can be associated with remarkable clinical benefit, but can also cause serious immune-related adverse events (irAEs). Management of rare and severe irAEs is challenged by an incomplete knowledge of their natural history and pathogenetic mechanisms. We report a case of fatal acute-onset gastro-intestinal (GI) hypomotility from myenteric plexus neuropathy following a single dose of ipilimumab plus nivolumab given for treatment of Merkel cell carcinoma (MCC). <h3>Case presentation</h3> A 66-year-old man with recurrent metastatic MCC involving several organs (liver, bones and disseminated retroperitoneal lymphadenopathy) developed profound pharyngeal dysphagia and ileus that started 7&nbsp;days after receiving a single administration of combination immune checkpoint blockade consisting of nivolumab (3&nbsp;mg/kg) and low-dose ipilimumab (1&nbsp;mg/kg). A swallowing study showed oropharyngeal dysfunction and aspiration. Imaging studies were consistent with diffuse intestinal paresis. An extensive work-up did not reveal obvious causes of these symptoms, and enteric plexopathy was suspected. Empiric immune suppressive therapy was initiated urgently. Despite an escalating immunosuppressive regimen that included high dose steroids, tacrolimus and therapeutic plasma exchange, no improvement in GI motility was seen and the patient suffered repeated episodes of aspiration. Seven weeks after the onset of GI hypomotility, the patient succumbed to sepsis from intestinal perforations. At autopsy, histologic specimens obtained from the entire GI tract (pharynx to rectum) showed near complete loss of ganglion cells within the myenteric and submucosal plexuses. An associated inflammatory infiltrate was not seen, suggesting a 'burned out' phase of illness. C4d complement deposition was found at the ganglionic sites, suggesting antibody-mediated pathogenesis. Remarkably, at sites of previously suspected Merkel cell metastases, no residual viable Merkel cell carcinoma was identified. <h3>Conclusions</h3> GI-tract paresis due to myenteric neuritis is a rarely reported toxicity of ICIs. Because the window of reversibility is likely to be very brief, quick and decisive interventions are warranted. Subtle functional and anatomic perturbations of the myenteric nervous system from the use of ICIs may be more prevalent than realized and should be suspected and addressed in both clinical and investigational settings.
Regorafenib in antiangiogenic-naive, chemotherapy-refractory advanced colorectal cancer: A phase IIb trial.
Authors: Rachel Pimenta Riechelmann, Luiz Antonio Senna Leite, Joao Glasberg, Giovanni Mendonca Bariani, Thomas Giollo Rivelli, Daniela R. Nebuloni, Fabiola Puty, Christian Kappeler, Kaline M. C. Pereira, Marcelo A Queiroz, Paulo Marcelo Hoff
Journal: Journal of Clinical Oncology (2018)

782 Background: The oral multikinase inhibitor regorafenib improves overall survival in advanced colorectal cancer (CRC). The aim of this study was to investigate the safety and efficacy of regorafenib in antiangiogenic-naïve patients with chemotherapy-refractory CRC. Methods: In this single-center, single-arm, phase 2b study, patients received regorafenib 160 mg/day for 3 weeks on/1 week off. Tumor response assessed by RECIST 1.1 and tumor metabolic response by [ 18 F] fluorodeoxyglucose positron emission tomography (PET/CT) according to the European Organization for Research and Treatment of Cancer (EORTC) criteria were evaluated at week 8 (W8). PFS rate was defined as the percentage of evaluable patients alive without progression at W8. Safety was assessed until the cut-off date (May 2, 2017). Results: Overall, 59 patients (59.3% male; median age 58.0 yrs) received regorafenib (median dose 148.8 mg/day). The W8 PFS rate was 46.6% (95% CI 33.3% - 60.1%) and median PFS and OS were 3.6 and 7.5 months, respectively. Overall disease control rate (DCR) was 50.8% by RECIST and 62.7% by EORTC criteria (Table). Most common regorafenib-related grade ≥3 AEs were hypertension (35.6%), hand-foot skin reaction (HFSR) (25.4%) and hypophosphatemia (22.0%). One patient discontinued treatment due to drug-related HFSR. Conclusions: The W8 PFS rate and overall DCR support the anti-tumor activity of regorafenib in antiangiogenic-naïve, chemotherapy-refractory advanced CRC. Compared with the previous phase 3 CORRECT and CONCUR trials, the median PFS suggests a better outcome in this population. These data provide the basis for further investigation of regorafenib’s role in earlier treatment lines in metastatic CRC and on the use of PET/CT in tumor response assessment. Clinical trial information: NCT02465502. [Table: see text]